Comparison of Intramyocardial and Intravenous Routes of Delivering Bone Marrow Cells for the Treatment of Ischemic Heart Disease: An Experimental Study
Abstract:The implantation of bone marrow cells (BMCs) into ischemic heart after myocardial infarction can induce angiogenesis and improve heart function. We compared the advantages of delivering BMCs intramyocardially and intravenously. An acute myocardial infarction model was created by the ligation of left anterior descending artery in female Dark Agouti rats. The rats were then randomly divided into four treatment groups: one given an intramyocardial injection of phosphate-buffered saline (PBS group), one given an intravenous injection of 2 × 107 BMCs from male rats (IV group), one given an intramyocardial injection with total of 2 × 107 BMCs from male rats at four points in the infarction area (IM group), and one given an intravenous injection of 10-fold the number of BMCs from male rats (10xIV group). Quantitative analysis of the SRY gene by real-time PCR showed that the survival of BMCs in the infarcted area was significantly higher in the IM group than in the IV and 10xIV groups, 3 days after treatment (p < 0.05), but not thereafter. However, the blood flow in the infarcted myocardium was significantly better in the IM and 10xIV groups than in the PBS and IV groups 14 days after treatment (p < 0.05). Echocardiography showed that the LVEF continued to decrease in the PBS and IV groups, but was stable after 3 days in the IM and 10xIV groups. By 14 days after treatment, the LVEF was significantly higher in the IM and 10xIV groups than in the PBS and IV groups (p < 0.01). Our results showed that BMCs were more effective delivered intramyocardially than intravenously for inducing angiogenesis and repairing injured myocardium.
Document Type: Research Article
Affiliations: Division of Cardiovascular Surgery, Department of Medical Bioregulation, Yamaguchi University School of Medicine, Minami-Kogushi 1-1-1, Ube, Yamaguchi, Japan 755-8505
Publication date: 2004-01-01
More about this publication?
- Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.